Pathophysiology and treatment of atherosclerosis Current view and future perspective on lipoprotein modification treatment by Bergheanu, S.C. et al.
REVIEW ARTICLE
DOI 10.1007/s12471-017-0959-2
Neth Heart J (2017) 25:231–242
Pathophysiology and treatment of atherosclerosis
Current view and future perspective on lipoprotein modification treatment
S. C. Bergheanu1,2 · M. C. Bodde3 · J. W. Jukema3
Published online: 13 February 2017
© The Author(s) 2017. This article is available at SpringerLink with Open Access.
Abstract Recent years have brought a significant amount
of new results in the field of atherosclerosis. A better under-
standing of the role of different lipoprotein particles in the
formation of atherosclerotic plaques is now possible. Re-
cent cardiovascular clinical trials have also shed more light
upon the efficacy and safety of novel compounds targeting
the main pathways of atherosclerosis and its cardiovascular
complications.
In this review, we first provide a background consist-
ing of the current understanding of the pathophysiology
and treatment of atherosclerotic disease, followed by our
future perspectives on several novel classes of drugs that
target atherosclerosis. The focus of this update is on the
pathophysiology and medical interventions of low-density
lipoprotein cholesterol (LDL-C), high-density lipoprotein
cholesterol (HDL-C), triglycerides (TG) and lipoprotein(a)
(Lp(a)).
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Atherosclerosis is a chronic condition in which arteries
harden through build-up of plaques. Main classical risk
factors for atherosclerosis include dyslipoproteinaemia, di-
abetes, cigarette smoking, hypertension and genetic abnor-
malities. In this review, we present an update on the patho-
physiology of atherosclerosis and related current and possi-
ble future medical interventions with a focus on low-density
lipoprotein cholesterol (LDL-C), high-density lipoprotein
cholesterol (HDL-C), triglycerides (TG) and lipoprotein(a)
(Lp(a)).
Pathophysiology of atherosclerosis
Hypercholesterolaemia is considered one of the main trig-
gers of atherosclerosis. The increase in plasma cholesterol
levels results in changes of the arterial endothelial per-
meability that allow the migration of lipids, especially
LDL-C particles, into the arterial wall. Circulating mono-
cytes adhere to the endothelial cells that express adhe-
sion molecules, such as vascular adhesion molecule-1
(VCAM-1) and selectins, and, consequently, migrate via
diapedesis in the subendothelial space [1]. Once in the
subendothelial space, the monocytes acquire macrophage
characteristics and convert into foamy macrophages. LDL
particles in the subendothelial space are oxidised and
become strong chemoattractants. These processes only
enhance the accumulation of massive intracellular choles-
terol through the expression of scavenger receptors (A, B1,
CD36, CD68, for phosphatidylserine and oxidised LDL) by
macrophages, which bind native and modified lipoproteins
and anionic phospholipids. The end result is a cascade
of vascular modifications [1] described in Table 1. Clini-
cal sequelae of atherosclerosis are vessel narrowing with
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Table 1 Vascular modifications
in atherosclerotic disease
Vascular modification Characteristics
Intimal thickening Layers of SMCs and extracellular matrix
More frequent in coronary artery, carotid artery, abdominal aorta, descend-
ing aorta, and iliac artery




Layers of SMCs in proteoglycan-collagen matrix aggregated near the lu-
men
Underlying lipid pool: acellular area rich in hyaluronan and proteoglycans
with lipid infiltrates
Fibroatheromas Acellular necrotic core (cellular debris)
Necrotic core is covered by a thick fibrous cap: SMCs in proteoglycan-col-
lagen matrix
Vulnerable plaque ‘Thin-cap fibroatheroma’
Type I collagen, very few/absent SMCs
Fibrous cap thickness is 65 µm
Ruptured plaque Ruptured fibrous cap
Presence of luminal thrombus
Larger necrotic core and increased macrophage infiltration of the thin
fibrous cap
SMCs smooth muscle cells
symptoms (angina pectoris) and acute coronary syndromes
due to plaque instability.
The majority of coronary thrombi are caused by plaque
rupture (55–65%), followed by erosions (30–35%), and
least frequently from calcified nodules (2–7%) [1]. Rup-
ture-prone plaques typically contain a large, soft, lipid-rich
necrotic core with a thin (65 µm) and inflamed fibrous
cap. Other common features include expansive remodelling,
large plaque size (>30% of plaque area), plaque haem-
orrhage, neovascularisation, adventitial inflammation, and
‘spotty’ calcifications. Vulnerable plaques contain mono-
cytes, macrophages, and T-cells. T-cells promote the vul-
nerability of plaques through their effects on macrophages
[2].
LDL-C, TG and HDL-C emerged as strong independent
predictors of atherosclerotic disease after the analysis of the
data from the Framingham study. While the role of other
parameters is being investigated, TC, LDL-C and HDL-C
remain to date the cornerstone in risk estimation for fu-
ture atherosclerotic events. Low HDL-C has been shown to
be a strong independent predictor of premature atheroscle-
rosis [3] and is included in most of the risk estimation
scores. Very high levels of HDL-C, however, have con-
sistently not been found to be associated with atheropro-
tection. The mechanism by which HDL-C protects against
atherosclerosis is still under debate and accumulating evi-
dence strongly suggests that the proportion of dysfunctional
HDL versus functional HDL rather than the levels may be
of importance.
Hypertriglyceridaemia (HTG) has been shown to be an
independent risk factor for cardiovascular disease (CVD).
Moreover, high TG levels are often associated with low
HDL-C and high levels of small dense LDL particles. The
burden of HTG is high, with about one-third of adult indi-
viduals having TG levels >1.7mmol/l (150mg/dL) [3].
Lp(a) is a specialised form of LDL and consists of an
LDL-like particle and the specific apolipoprotein (apo) A.
Elevated Lp(a) is an additional independent risk marker and
genetic data made it likely to be causal in the pathophysiol-




Medication to adequately control lipoprotein levels needs
to be initiated when risk reduction through lifestyle modifi-
cations such as dietary changes, stimulation of physical ac-
tivity and smoking cessation is not sufficient. In secondary
prevention, medical therapy is almost invariably needed in
addition to lifestyle optimisation.
LDL-C-lowering therapy
HMG-CoA reductase inhibitors (statins) 3-hydroxy-3-
methyl–glutaryl-coenzyme A (HMG-CoA) reductase in-
hibitors (usually addressed as ‘statins’) induce an increased
expression of LDL receptors (LDL-R) on the surface of the
hepatocytes, which determines an increase in the uptake
of LDL-C from the blood and a decreased plasma concen-
tration of LDL-C and other apo B-containing lipoproteins,
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Since the 1990s, statin therapy has shown its effect on
cardiovascular outcome in several major landmark trials,
summarised in Table 2.
Independent of baseline LDL-C level and baseline car-
diovascular (CV) risk, meta-analyses concerning up to 27
statin CV outcome trials, showed a 22% risk reduction in
CV events per 1mmol/l reduction in LDL-C ([5–7]; Fig. 1).
It is currently known that both the baseline burden of
atherosclerotic plaque and the degree of progression on se-
rial evaluation significantly associate with risk of CV events
[8, 9]. The difference in change in percent atheroma volume
(PAV) between patients with and without an event can be
as low as approximately 0.55% [10].
Not reaching the cholesterol treatment goals and non-
compliance are two important causes for statin therapy fail-
ure. Although the LDL-C levels obtained in clinical trials
are often low, the clinical reality seems different. Vonbank
et al. [11] showed that in 2 cohorts of high-risk CV patients,
one from 1999–2000 and the other one from 2005–2007,
only 1.3% and 48.5% of patients, respectively, had the LDL-
C < 1.8mmol/l at 2-year follow-up. The fear of possible
side effects of statin therapy is an important reason for non-
compliance and remains an underestimated problem in clin-
ical practice. One study in high-dose statin patients reported
that muscular pain prevented even moderate exertion during
everyday activities in 38% of patients, while 4% of patients
were confined to bed or unable to work [12]. Jukema et al.
reviewed available data and concluded that statin use is as-
sociated with a small increase in type 2 diabetes mellitus
incidence, but no convincing evidence was found for other
major adverse effects such as cognitive decline or cancer
[13].
Statins are therefore, in general, very efficient drugs that
in an overwhelming amount of well conducted clinical tri-
als showed consistent clinical event reductions with a very
good safety profile. Nevertheless, side effects of importance
may occur making the compound, as in any drug class,
sometimes unsuitable for some individual patients.
Cholesterol absorption inhibitors By inhibiting choles-
terol absorption, ezetimibe reduces LDL-C. In clinical stud-
ies, ezetimibe as monotherapy reduced LDL-C by 15–22%
and when combined with a statin it induced an incremental
reduction in LDL-C levels of 15–20% [3]. No frequent
major adverse effects have been reported [3]. Results from
studies like PRECISE-IVUS [14] and IMPROVE-IT [15]
support the use of ezetimibe as second-line therapy in
association with statins when the therapeutic goal is not
achieved at the maximum tolerated statin dose, in statin-
intolerant patients, or in patients with contraindication to
statins [3].
Bile acid sequestrants At the highest dose, cholestyra-
mine, colestipol or the recently developed colesevelam can
produce a reduction in LDL-C of 18–25% [3]. The use of
cholestyramine and colestipol is limited by gastrointestinal
adverse effects and major drug interactions with other fre-
quently prescribed drugs. Colesevelam appears to be better
tolerated and to have less interaction with other drugs and
can be combined with statins. Relatively little hard evidence
is available from large clinical trials for this class of drugs.
Proprotein convertase subtilisin/kexin type-9 inhibitors
Inhibitors of proprotein convertase subtilisin/kexin type-9
(PCSK-9) offer the prospect of achieving even lower LDL-
C levels than statins in combination with ezetimibe. PCSK-
9 binds to LDL-R at the liver and stimulates the absorption
and degradation of these receptors. Through inhibition of
PCSK-9, the degradation of LDL-R is prevented thereby
improving the absorption by the liver of LDL-C particles,
which consequently leads to lower LDL-C plasma concen-
trations.
In 2015, reports were published from two phase 3 trials
that measured the efficacy and safety of evolocumab and
alirocumab, two monoclonal antibodies that inhibit PCSK-
9 [16, 17]. In these trials, the PCSK-9 therapy signifi-
cantly lowered LDL-C by  50% and in a preliminary
(not powered) analysis reduced the incidence of CV events
(Table 3). Other promising results were published from the
GLAGOV [18] trial and demonstrated a significant percent-
age atheroma volume decrease with evolocumab (Table 3).
Both evolocumab and alirocumab have been recently ap-
proved by the European Medicine Agency and the US
Food and Drug Administration for the treatment of ele-
vated plasma LDL-C. The PCSK-9 therapy is suitable in
a wide range of patients provided that they express LDL-R,
including those with heterozygous and homozygous famil-
ial hypercholesterolaemia with residual LDL-R expression
[3]. Relatively high costs of the compounds and yet the
lack of hard outcomes in large randomised controlled trials
(RCTs) still limit their use in clinical practice.
The first results of two large RCTs investigating the long-
term efficacy and safety of evolocumab (FOURIER trial)
and alirocumab (ODYSSEY Outcomes trial) are under-
way and necessary [19, 20]. Recently, the development of
another monoclonal PCSK-9 inhibitor, bococizumab, was
stopped due to auto-antibodies formation against the com-
pound that significantly reduced the LDL-C-lowering effi-
cacy (The SPIRE program) [21].
TG-lowering therapy
Statins Statins reduce the plasma concentration of TG-
rich particles by inhibiting HMG-CoA reductase. Although
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Table 2 Summary of major clinical trials and programs involving low-density lipoprotein cholesterol lowering treatments
Drug/Target Clinical trial Study size Duration CV endpoints Results
Statins 4 S [44] 4444 patients with CHD 5.4 y Coronary death 111 in the simvastatin group; 189 in the
placebo group; (RR = 0.58, 95% CI:
0.46–0.73)
WOSCOP [45] 6595 men with hyperc-
holesterolemia
4.9 y Combined nonfa-
tal MI/coronary
death
174 in the pravastatin group; 248 in the
placebo group; (RRR = 31%, 95% CI:
17–43%)
CARE [46] 4159 subjects with high
CV risk and normal
LDL-C levels
4.9 y Combined coro-
nary event/
nonfatal MI
10.2% in the pravastatin group; 13.2%




349 patients on statin ther-
apy with serial IVUS ex-
aminations
2.0 y IVUS change in
PAV




1039 patients with CAD
on intensive statin treat-
ment
2.0 y IVUS change in
PAV
–0.99% (–1.19 to –0.63%) in the
atorvastatin group; –1.22% (–1.52 to
–0.90%) in the pravastatin group
REGRESS [9] 885 symptomatic male
patients on pravastatin or
placebo
2.0 y Change in lumen
diameter
0.10mm decrease in the placebo group;
0.06mm decrease in the pravastatin
group (p = 0.019)
PROVE-IT
TIMI 22 [10]
4162 ACS patients on
either intensive or standard
statin therapy
2.0 y Combined death,
MI, UAP, revascu-
larization, stroke
22.4% in intensive therapy group;
26.3% in standard statin therapy group;




PCI on statin alone or
statin + ezetimibe
9.9m IVUS change in
PAV
–1.4% (–3.4 to –0.1%) in the dual lipid
lowering group; –0.3% (–1.9 to 0.9%)
in the statin monotherapy group
IMPROVE-IT
[15]
18,114 ACS patients on
statin + placebo or on
statin + ezetimibe
6.0 y Combined death,
MI, UAP, revascu-
larization, stroke
32.7% in simvastatin + ezetimibe
group; 34.7% in the simvastatin +








7.4 y Combined CAD
death/nonfatal
acute MI
8.1% in cholestyramine group; 9.8% in




OSLER [16] 4465 patients on
evolocumab + standard





–61% (–59 to –63%) LDL-C change
in the evolocumab group, 0.95% even-
t-rate in the evolocumab group; 2.18%
in the standard therapy group; (HR




2341 high risk patients







–61% LDL-C change in the alirocumab
group; 0.8% in the placebo group;
(p < 0.001). 1.7% event-rate in the
alirocumab group; 3.3% in the placebo
group; (HR 0.52, 95% CI: 0.31–0.90)
GLAGOV [18] 968 presenting for CAG
randomized with either
evolocumab or placebo
76w IVUS change in
PAV
–1.0% (–1.8 to –0.64%) in the
evolocumab group
CHD coronary heart disease, CAD coronary artery disease MI myocardial infarction, CV cardiovascular risk, LDL-C low-density lipoprotein
cholesterol, PAV percentage atheroma volume, ACS acute coronary syndrome, PCI percutaneous coronary intervention, UAP unstable angina
pectoris, CAG coronary angiography, IVUS intravascular ultrasonography, y year, m months, RR relative risk, HR hazard ratio, CI confidence
interval, 4S Scandinavian Simvastatin Survival Study, WOSCOP West of Scotland Coronary Prevention, CARE Cholesterol and Recurrent
Events, ASTEROID A Study to Evaluate the Effect of Rosuvastatin on Intravascular Ultrasound – Derived Coronary Atheroma Burden,
SATURN The Study of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin versus Atorvastatin, REGRESS The Regression
Growth Evaluation Statin Study, REVERSAL Reversal of Atherosclerosis with Aggressive Lipid Lowering, PROVE-IT TIMI 22 pravastatin
or atorvastatin evaluation and infection trial-thrombolysis in myocardial infarction, PRECISE-IVUS Plaque Regression With Cholesterol
Absorption Inhibitor or Synthesis Inhibitor Evaluated by Intravascular Ultrasound, IMPROVE-IT IMProved Reduction of Outcomes: Vytorin
Efficacy International Trial, LRC-CPP Lipid Research Clinics Coronary Primary Prevention, OSLER open-label study of long-term evaluating
against LDL-C, ODYSSEY LONG TERM Long-term Safety and Tolerability of Alirocumab in High Cardiovascular Risk Patients with
Hypercholesterolemia Not Adequately Controlled with Their Lipid Modifying Therapy, GLAGOV global assessment of plaque regression with
a PCSK-9 antibody as measured by intravascular ultrasound
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Fig. 1 Relation between proportional reduction in incidence of ma-
jor coronary events and major vascular events and mean absolute LDL
cholesterol reduction at 1 year. Square represents a single trial plotted
against mean absolute LDL cholesterol reduction at 1 year, with ver-
tical lines above and below corresponding to one SE of unweighted
event rate reduction. Trials are plotted in order of magnitude of dif-
ference in LDL cholesterol difference at 1 year. For each outcome,
regression line (which is forced to pass through the origin) represents
weighted event rate reduction per mmol/l LDL cholesterol reduction.
(Figure published with permission of the Lancet (owned by Elsevier))
recent evidence positions HTG as a CV risk factor, the
benefits of lowering elevated TG levels are still modest.
Statins are the first-choice therapy in patients with HTG
since they reduce both the CV risk and, in high doses,
have a stronger effect on elevated TG levels (up to 27%
reduction) [3, 22].
Fibrates Fibrates are agonists of peroxisome prolifera-
tor-activated receptor-α (PPAR-α), acting via transcription
factors regulating various steps in lipid and lipoprotein
metabolism. Fibrates have good efficacy in lowering fast-
ing TG as well as post-prandial TGs and TG-rich lipopro-
tein remnant particles, with lowering TG levels up to more
than 50% [23]. However, results from 5 prospective RCTs
and 5 meta-analyses failed to demonstrate superior CV out-
comes with fibrates, especially when used on top of statins
[3].
n-3 fatty acids n-3 fatty acids (eicosapentaenoic acid
(EPA) and docosahexaenoic acid (DHA)) can lower TG
possibly through interaction with PPARs. Although the
underlying mechanism is poorly understood n-3 fatty acids
can reduce TG levels with up to 45%. A meta-analysis
of 20 studies and 63,000 patients found no overall effect
of omega-3 fatty acids on composite CV events. n-3 fatty
acids appear to be safe and not interact with other therapies
[24].
Currently, there are two ongoing phase 3 randomised
placebo-controlled clinical trials evaluating the effect of
EPA on CV outcomes in 21,000 subjects with elevated
serum TG [25, 26]. If TG are not controlled by statins
or fibrates n-3 fatty acids may be added to decrease TG
further, as these combinations are safe and well tolerated
[3].
HDL-C increasing therapy
Even though lifestyle changes may increase HDL-C levels
to a certain degree, many patients will also require medi-
cation should a robust HDL-C increase be considered nec-
essary. To date, there is no convincing evidence that arti-
ficially raising HDL-C leads to an improved CV outcome.
However, if HDL-C increasing therapy is considered then
the following options are available.
Cholesteryl ester transfer protein (CETP) inhibitors
The inhibition of CETP by small molecule inhibitors repre-
sents currently the most efficient pharmacological approach
to influence low HDL-C, with an effect of ≥100% increase
in HDL-C and frequently a reduction of LDL-C levels as
well. Despite the impressive HDL-C increase, no effect has
been seen yet on CV endpoints, as all the CETP-inhibitors
studies [27–29] have failed to demonstrate this thus far.
Torcetrapib was discontinued following a higher mor-
tality in the torcetrapib arm of the ILLUMINATE trial
[27], the results of the dalcetrapib trial (Dal-OUTCOMES)
showed no clinical impact in acute coronary patients and
the ACCELERATE trial of evacetrapib in acute coronary
patients on statins was terminated prematurely due to lack
of efficacy signals [28, 29].
238 Neth Heart J (2017) 25:231–242
Table 3 Trials concerning PCSK-9 inhibition
Clinical trial Mechanism of
action











































CAD coronary artery disease, MI myocardial infarction, CV cardiovascular risk, LDL-C low-density lipoprotein cholesterol, UAP unstable angina
pectoris, ACS acute coronary syndrome, ASCVD atherosclerotic cardiovascular disease, PCSK-9 proprotein convertase subtilisin/kexin type-9,
siRNA small interfering RNA, ODYSSEY Safety and Tolerability of Alirocumab in High Cardiovascular Risk Patients with Hypercholesterolemia
Not Adequately Controlled with Their Lipid Modifying Therapy, FOURIER Further cardiovascular OUtcomes Research with PCSK9 Inhibition
in subjects with Elevated Risk, SPIRE Studies of PCSK9 Inhibition and the Reduction of vascular Events, ORION Trial to Evaluate the Effect of
ALN-PCSSC Treatment on Low-density Lipoprotein Cholesterol
Of the CETP inhibitors initially developed, only anace-
trapib is still active. In mice models it has been reported
that anacetrapib attenuates atherosclerosis not by increas-
ing HDL-C but rather by decreasing LDL-C by CETP in-
hibition and by a CETP independent reduction of plasma
PCSK-9 level [30].
The REVEAL study, a very large phase 3 RCT with
anacetrapib, is still underway and its results are expected
in 2017 [31]. This trial will further elucidate whether the
additional beneficial effects of anacetrapib on top of a statin
can be translated into clinical benefit.
Statins Statins produce elevations in HDL-C levels be-
tween 5–10% [32]. It is difficult to extract the amount of
effect that HDL-C increase might have in the overall ob-
served CV risk reduction with statins.
Fibrates Fibrates increase HDL-C in a similar proportion
with statins, namely between 5% in long-term trials (espe-
cially if type 2 DM patients are included) and up to 15%
in short-term studies [23, 33]. The FIELD study failed to




PCSK-9 inhibition (non-monoclonal antibody) A re-
cent approach in decreasing PCSK-9 levels is the ad-
ministration of small interfering RNA (siRNA) molecules
directed against PCSK-9. The siRNA molecules enable the
RNA-induced silencing complex, which cleaves messenger
RNA (mRNA) molecules encoding PCSK-9 specifically.
The cleaved mRNA is degraded and thus unavailable for
protein translation, which results in decreased levels of
the PCSK-9 protein. The phase 2 ORION trial showed
that one subcutaneous injection of 300mg inclisiran de-
termined a mean LDL-C reduction of 51% after 6 months
[34]. Inclisiran was well tolerated with no relevant safety
concerns. These results support the start of the phase 3
program. The next step might be the development of a vac-
cine targeting PCSK-9. Crossey et al. provided in mice and
macaques the proof-of-principle evidence that a vaccine
targeting PCSK-9 peptide can effectively lower lipid levels
and works synergistically with statins [35].
Bempedoic acid Bempedoic acid is a first-in-class adeno-
sine triphosphate (ATP) Citrate Lyase inhibitor. The mech-
anism of action involves the inhibition of cholesterol
biosynthesis and the up-regulation of LDL-R, which in
turn decreases plasma LDL-C levels. A phase 3 clinical
trial (CLEAR Harmony) is currently conducted in patients
with high CV risk and elevated LDL-C that is not ad-
equately controlled under their current therapy. Almost
2000 subjects will be randomised for bempedoic acid or
placebo and will be followed for 52 weeks [36]. In con-
tinuation of this trial, the CLEAR Outcomes trial will be
conducted. This will be an event-driven study of 12,600
patients on either bempedoic acid or placebo with the pri-
mary efficacy endpoint of major adverse CV events. The
results of this trial will be expected not earlier than 2022.
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Table 4 Ongoing trials and future perspective
Target Clinical trial Mechanism of
action





ACL-inhibitor Bempedoic acid 1950 high
CV risk
patients






2 Effect on LDL-C Full results –
early 2017


















2 Change in PAV No significant
effect




2 Change in PAV Early 2017






































1/2 %change in fasting
Lp(a)
–92%
LDL-C low-density lipoprotein cholesterol, ATP adenosine triphosphate, ACL-inhibitor ATP-Citrate Lyase inhibitor, PPARδ peroxisome prolifera-
tor-activated receptor delta, HoFH homozygous familiar hypercholesterolemia, CV cardiovascular, ACS acute coronary syndrome, PAV percentage
atheroma volume, PK pharmacokinetics, PD pharmacodynamics, ApoA-I apolipoprotein A-I, MI myocardial infarction, PAD peripheral arterial
disease, CETP cholesteryl ester transfer protein, LPL lipoprotein lipase, Lp(a) lipoprotein (a), mRNA messenger RNA, MILANO-PILOT MD-
CO-216 Infusions Leading to Changes in Atherosclerosis: A Novel Therapy in Development to Improve Cardiovascular Outcomes – Proof of
Concept Intravascular Ultrasound (IVUS), Lipids, and Other Surrogate Biomarkers Trial, CARAT CER-001 Atherosclerosis Regression ACS Trial,
AEGIS The ApoA-I Event Reduction in Ischemic Syndromes I, REVEAL Randomized EValuation of the Effects of Anacetrapib though Lipid-
modification, IONIS ANGPTL3-LRx IONIS Angiopoietin-like 3-linear RNAx
Peroxisome proliferator-activated receptor delta
(PPARδ) PPARδ is a nuclear receptor that regulates
genes involved in lipid storage and transport. MBX-8025
is a selective agonist for PPARδ.
The recently presented partial results from a proof-of-
concept phase II trial in patients with homozygous familial
hypercholesterolaemia showed that the range of responses
to MBX-8025 was broad, but that MBX-8025 could provide
a clinically meaningful reduction in LDL-C for a subset of
patients [37].
Other lipoprotein modification targets
Apo A-I mimetics Apo A-I is the primary functional
component of HLD-C and supports the rapid removal of
cholesterol from plaque. The MILANO-PILOT study was
a proof-of-concept study in which the impact on coronary
plaque by MDCO-216 was measured in 120 acute coro-
nary syndrome (ACS) patients using IVUS [38]. MDCO-
216 is a complex of dimeric recombinant apolipoprotein A-
I Milano and a phospholipid (POPC), and mimics pre-beta
HDL. In this study, MDCO-216 did not produce a signifi-
cant effect on coronary progression. Based on these results
further development of the compound was halted. CER-
001 is a different engineered pre-beta HDL compound and
is currently being tested in a phase 2 clinical trial (CARAT)
assessing the nominal change from baseline to follow-up
(at 12 weeks) in the PAV in the target coronary artery of
ACS patients. Results will be available in early 2017 [39].
CSL112 is a plasma-derived apolipoprotein A-I (apo A-I)
and was tested in a phase II trial for safety and tolerability.
CSL112 was well tolerated and did not significantly alter
liver or kidney functions [40]. Assessment of the efficacy
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of CSL112 will be performed in an adequately powered
phase 3 clinical trial.
Angiopoietin-like 3 (ANGPTL3) ANGPTL3 is a protein
and main regulator of lipoprotein metabolism. Its function is
linked to the inhibition of lipoprotein lipase (LPL) activity.
Earlier studies have identified that subjects with ANGPTL3
deficiency have reduced cholesterol and TG levels. Re-
cently, a phase 1/2 study evaluated the safety, tolerability,
pharmacokinetics and pharmacodynamics of ANGPTL3-
LRx (an antisense inhibitor of ANGPTL3) in healthy vol-
unteers with elevated TG and subjects with familial hyperc-
holesterolaemia. There were no short-term safety concerns
and ANGPTL3-LRx induced significant mean reductions
in TGs (66%), LDL-C (35%) and total cholesterol (36%).
Final results are expected in 2017 [41].
Lipoprotein(a) (Lp(a)) PCSK-9 inhibitors and nicotinic
acid reduce Lp(a) by approximately 30% [16, 17, 42],
however, an effect on CV events targeting Lp(a) has not
been convincingly shown. A phase 2 clinical trial showed
that IONIS-APO(a)Rx, an oligonucleotide targeting Lp(a),
induced a lowering of Lp(a) levels of up to 71.6% [43].
A phase 1/2a first-in-man trial showed that IONIS-APO(a)-
LRx, a ligand-conjugated antisense oligonucleotide de-
signed to be highly and selectively taken up by hepato-
cytes, induced a lowering of Lp(a) levels of up to 92%.
Both antisense oligonucleotides were short-term safe and
well tolerated [43].
Plasma Lp(a) is currently not recommended for risk
screening in the general population, but measurement
should be considered in people with high CV risk or
a strong family history of premature atherothrombotic
disease [3].
Table 4 provides an overview of the most important on-
going lipoprotein modifying trials and their expected or
recently published results.
Conclusions
Lowering LDL-C by statin therapy remains, to date, the
cornerstone for the medical prevention and treatment of
atherosclerotic disease since it is efficient and generally
safe. In high-risk patients with statin intolerance or in high-
risk patients who do not obtain the desired LDL-C level
with intensive statin treatment, cholesterol absorption in-
hibitors, especially ezetimibe, should be considered. Bile
acid sequestrants, fibrates and niacin are not recommended.
Upcoming PCSK-9 inhibitors, whether in the form of mon-
oclonal antibodies or new approaches, appear as potent
agents for dyslipoproteinaemia. However, their long-term
efficacy and safety still needs to be proven and costs may
limit their practical use. HDL-C modulation through CETP
inhibition and apo A-I mimetics did not yet provide evi-
dence for better CV outcomes; the REVEAL and CARAT
trials will shed light on the future of these drug classes. New
classes of molecules targeting ANGPTL3 and Lp(a) have
shown promising efficacy and good short-term safety pro-
files in several early phase trials and these results warrant
further development.
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